Vestal Point Capital LP Raises Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Vestal Point Capital LP lifted its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 19.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,770,000 shares of the specialty pharmaceutical company's stock after purchasing an additional 770,000 shares during the period. KalVista Pharmaceuticals comprises about 2.4% of Vestal Point Capital LP's investment portfolio, making the stock its 14th largest position. Vestal Point Capital LP owned 9.65% of KalVista Pharmaceuticals worth $40,402,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. bought a new position in KalVista Pharmaceuticals during the 4th quarter worth about $634,000. SG Americas Securities LLC lifted its position in shares of KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock valued at $123,000 after buying an additional 1,319 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 5,502 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of KalVista Pharmaceuticals by 14.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company's stock valued at $5,895,000 after buying an additional 89,001 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of KalVista Pharmaceuticals by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company's stock valued at $1,041,000 after buying an additional 4,940 shares during the last quarter.

KalVista Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ:KALV traded up $0.05 during trading on Friday, hitting $11.47. 368,958 shares of the stock traded hands, compared to its average volume of 421,611. The company has a fifty day moving average price of $11.96 and a two-hundred day moving average price of $10.45. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $15.50. The company has a market cap of $570.24 million, a price-to-earnings ratio of -3.15 and a beta of 0.05.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Jones Trading reissued a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an "outperform" rating and a $19.00 price target for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $24.83.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of the stock in a transaction on Wednesday, April 9th. The shares were bought at an average price of $9.42 per share, with a total value of $235,500.00. Following the purchase, the insider now directly owns 5,303,985 shares in the company, valued at $49,963,538.70. This trade represents a 0.47% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 3,808 shares of the business's stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $45,086.72. Following the transaction, the chief executive officer now directly owns 293,367 shares in the company, valued at approximately $3,473,465.28. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 15,647 shares of company stock valued at $181,770. 10.50% of the stock is owned by company insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).